{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:29:36Z","timestamp":1790418576750,"version":"4.1.0"},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"Suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:p>The onset of the COVID-19 pandemic challenged healthcare systems focusing their activity on patients infected with SARS-CoV-2. Previous experience with co-infections and superinfections in patients infected with other coronaviruses (SARS-CoV and MERS), the influenza patients admitted to hospitals and prevention of the unknown led to the increased empirical use of broad-spectrum antibiotics in hospitals. The breakdown of antimicrobial stewardship and infection control programs determine an increase in infections due to multidrug-resistant bacteria, particularly in intensive care units. Most of these infections are related to high-risk carbapenemase-producing clones and occasionally with resistance to new \u03b2-lactam-\u03b2-lactamase inhibitor combinations. On the contrary, in the primary care, there has been a decrease in the use of antimicrobials during the first wave, although it would not have had a significant impact on pathogens associated with community-acquired infections. The accumulated experience reaffirms the need to maintain antimicrobial stewardship and infection control programs in future health crises.<\/jats:p>","DOI":"10.37201\/req\/s01.19.2021","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T06:58:37Z","timestamp":1633157917000},"page":"63-68","source":"Crossref","is-referenced-by-count":37,"special_numbering":"Suppl 1","title":["COVID-19: Impact on prescribing and antimicrobial resistance"],"prefix":"10.37201","volume":"34","author":[{"given":"Patricia","family":"Ruiz-Garbajosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Servicio de Microbiolog\u00eda. Hospital Universitario Ram\u00f3n y Cajal and Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS). Madrid. Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"23328","published-online":{"date-parts":[[2021,9,30]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":[],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T08:02:29Z","timestamp":1633161749000},"score":1,"resource":{"primary":{"URL":"https:\/\/seq.es\/abstract\/rev-esp-quimioter-2021-september-19\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":0,"journal-issue":{"issue":"Suppl 1","published-online":{"date-parts":[[2021,9,30]]},"published-print":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/s01.19.2021","relation":{},"ISSN":["0214-3429","1988-9518"],"issn-type":[{"value":"0214-3429","type":"print"},{"value":"1988-9518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}